Skip to main content
Zenas BioPharma, Inc. logo

Zenas BioPharma, Inc. — Investor Relations & Filings

Ticker · ZBIO ISIN · US98937L1052 US Manufacturing
Filings indexed 147 across all filing types
Latest filing 2026-05-13 Interim / Quarterly Rep…
Country US United States of America
Listing US ZBIO

About Zenas BioPharma, Inc.

https://zenasbio.com/

Zenas BioPharma is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of transformative therapies for autoimmune diseases. The company is advancing a pipeline of immunology-based treatments to address significant unmet patient needs. Its two late-stage franchises are obexelimab and orelabrutinib. Obexelimab is an investigational bifunctional monoclonal antibody designed to suppress B cell activity by co-engaging CD19 and FcγRIIb. Orelabrutinib is an investigational, highly selective, CNS-penetrant oral small molecule BTK inhibitor. Zenas aims to become a global leader in providing innovative treatments for patients with autoimmune conditions.

Recent filings

Filing Released Lang Actions
10-Q - Zenas BioPharma, Inc. (0001953926) (Filer)
Interim / Quarterly Report
2026-05-13 English
8-K - Zenas BioPharma, Inc. (0001953926) (Filer)
Regulatory Filings
2026-05-13 English
424B5 - Zenas BioPharma, Inc. (0001953926) (Filer)
Prospectus
2026-03-30 English
424B5 - Zenas BioPharma, Inc. (0001953926) (Filer)
Prospectus
2026-03-30 English
FWP - Zenas BioPharma, Inc. (0001953926) (Subject)
Regulatory Filings
2026-03-27 English
FWP - Zenas BioPharma, Inc. (0001953926) (Subject)
Regulatory Filings
2026-03-27 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.